Dossier assessment
Teclistamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Teclistamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Teclistamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy
Added benefit not proven
Project details
- Project no.
- A23-91
- Commission
- Commission awarded on 01.09.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://dx.doi.org/10.60584/A23-91